Riomet

Diabetic Ketoacidosis, Congestive Heart Failure, Type 1 Diabetes + 16 more
Treatment
21 FDA approvals
20 Active Studies for Riomet

What is Riomet

MetforminThe Generic name of this drug
Treatment SummaryMetformin is a medication used to treat type 2 diabetes. It works by reducing blood sugar levels without causing hypoglycemia (low blood sugar). It also helps to improve insulin sensitivity, lower fasting insulin levels, and can lead to modest weight loss. Metformin was first approved in Canada in 1972 and in the USA in 1995, and is available in regular and extended-release forms. It is the most commonly prescribed drug for type 2 diabetes, with more than 120 million people taking it worldwide.
Metformin Hydrochlorideis the brand name
Riomet Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Metformin Hydrochloride
Metformin
2002
1263

Approved as Treatment by the FDA

Metformin, otherwise known as Metformin Hydrochloride, is approved by the FDA for 21 uses which include Type 2 Diabetes Mellitus and Ejection fraction decreased .
Type 2 Diabetes Mellitus
Used to treat Type 2 Diabetes Mellitus in combination with Dapagliflozin
Ejection fraction decreased
Used to treat Ejection fraction decreased in combination with Dapagliflozin
Type 2 Diabetes
Used to treat Type 2 Diabetes Mellitus in combination with Dapagliflozin
Chronic Kidney Disease
Used to treat Chronic Kidney Disease (CKD) in combination with Dapagliflozin
Heart Failure
Used to treat NYHA Functional Class II-IV Heart Failure in combination with Dapagliflozin
Kidney Failure
Used to treat End Stage Renal Disease (ESRD) in combination with Dapagliflozin
Ketosis
Used to treat Diabetic Ketoacidosis in combination with Saxagliptin
Diet
Used to treat Diet in combination with Dapagliflozin
Hospitalizations
Used to treat Hospitalizations in combination with Dapagliflozin
Congestive Heart Failure
Used to treat Heart Failure in combination with Dapagliflozin
Physical Activity
Used to treat Exercise in combination with Dapagliflozin
Chronic Kidney Disease (CKD)
Used to treat Chronic Kidney Disease (CKD) in combination with Dapagliflozin
Type 1 Diabetes Mellitus
Used to treat Type 1 Diabetes Mellitus in combination with Sitagliptin
Diabetic Ketoacidosis
Used to treat Diabetic Ketoacidosis in combination with Saxagliptin
Cardiovascular Mortality
Used to treat Cardiovascular Mortality in combination with Dapagliflozin
Renal Insufficiency
Used to treat decreased estimated glomerular filtration rate in combination with Dapagliflozin
Diabetes Mellitus
Used to treat uncontrolled diabetes in combination with Rosiglitazone
Cardiovascular Disease
Used to treat Cardiovascular Risk in combination with Dapagliflozin
Cardiovascular Diseases
Used to treat established cardiovascular disease in combination with Dapagliflozin
Heart failure
Used to treat Heart Failure in combination with Dapagliflozin
Type 1 Diabetes
Used to treat Type 1 Diabetes Mellitus in combination with Sitagliptin

Effectiveness

How Riomet Affects PatientsInsulin is a hormone that helps control blood sugar levels. People with type 2 diabetes have decreased sensitivity to insulin, which leads to higher blood sugar levels. Metformin works by reducing the amount of sugar made by the liver, stopping sugar from being absorbed by the gut, and making the body more sensitive to insulin. Metformin does not cause too much insulin to be released like some other diabetes drugs, but it can still help lower blood sugar levels. In a 29 week study of people with type 2 diabetes, taking metformin lowered fasting blood sugar by an average of 59 mg/dL and lowered glycosylated hemoglobin
How Riomet works in the bodyMetformin works in the body to help control blood sugar levels in people with type 2 diabetes. It does this by decreasing the amount of sugar produced by the liver, reducing the amount of sugar absorbed in the intestines, and increasing the body's sensitivity to insulin. When metformin enters the body, it is taken up by the liver cells and accumulates in the mitochondria. This leads to a decrease in the production of energy, which activates an enzyme called AMPK. Activated AMPK then helps to reduce fat synthesis and glucose production, while also helping the body use glucose more effectively. In the intestines, metform

When to interrupt dosage

The proposed measure of Riomet is contingent upon the established condition, including Diet, inadequate answer to metformin and Diabetic Ketoacidosis. The quantity of dosage fluctuates as per the delivery approach (e.g. Oral or Tablet - Oral) listed in the table underneath.
Condition
Dosage
Administration
Renal Insufficiency
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Cardiovascular Diseases
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Diabetes Mellitus
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Congestive Heart Failure
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Type 2 Diabetes
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Chronic Kidney Disease
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Diabetic Ketoacidosis
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Physical Activity
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Kidney Failure
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Diet
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Hospitalizations
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Heart Failure
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Insulin Resistance
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
inadequate response to metformin
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Type 1 Diabetes
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Polycystic Ovarian Syndrome
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Cardiovascular Disease
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Cardiovascular Mortality
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral
Ejection fraction decreased
500.0 mg, , 1000.0 mg, 750.0 mg, 850.0 mg, 250.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg
Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, , Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet, Kit, Solution, Solution - Oral, Tablet, coated - Oral, Tablet, coated, For suspension, extended release, For suspension, extended release - Oral, Kit - Oral

Warnings

Riomet has twenty contraindications and should not be administered simultaneously with the conditions outlined in the following table.Riomet Contraindications
Condition
Risk Level
Notes
Liver Failure
Do Not Combine
Renal Insufficiency
Do Not Combine
Heart Arrest
Do Not Combine
Diabetic Ketoacidosis
Do Not Combine
Operative Surgery
Do Not Combine
Metabolic acidosis
Do Not Combine
Heart Failure
Do Not Combine
Renal Insufficiency
Do Not Combine
kidney function unknown
Do Not Combine
Hypovolemic Shock
Do Not Combine
serum creatinine above upper limit for age range
Do Not Combine
ethanol
Do Not Combine
Acute Coryza
Do Not Combine
Hypoxemia
Do Not Combine
Liver Failure
Do Not Combine
Acidosis, Lactic
Do Not Combine
Diabetic Ketoacidosis
Do Not Combine
Renal Insufficiency
Do Not Combine
Renal Insufficiency, Chronic
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Metformin may interact with Pulse Frequency
There are 20 known major drug interactions with Riomet.
Common Riomet Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Metformin.
Procainamide
Major
The excretion of Procainamide can be decreased when combined with Metformin.
Topotecan
Major
The excretion of Topotecan can be decreased when combined with Metformin.
Abacavir
Minor
Metformin may decrease the excretion rate of Abacavir which could result in a higher serum level.
Aclidinium
Minor
Metformin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Riomet Toxicity & Overdose RiskThe toxic dose of Metformin (hydrochloride) for rats is 1g/kg orally, 500mg/kg intraperitoneally, and 300mg/kg subcutaneously. For mice, the toxic dose is 1450mg/kg orally, 420mg/kg intraperitoneally, and 225mg/kg subcutaneously. Taking too much Metformin may increase the risk of lactic acidosis, which can cause symptoms such as malaise, muscle pain, abdominal pain, and difficulty breathing. Metformin should be avoided in those with severely impaired kidney function, acute or decompensated heart
image of a doctor in a lab doing drug, clinical research

Riomet Novel Uses: Which Conditions Have a Clinical Trial Featuring Riomet?

A total of 346 active clinical trials are being conducted to assess the potential of Riomet in treating Type 2 Diabetes, Type 1 Diabetes and inadequate response to metformin therapy.
Condition
Clinical Trials
Trial Phases
Chronic Kidney Disease
102 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3, Early Phase 1
Cardiovascular Diseases
0 Actively Recruiting
Congestive Heart Failure
184 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3, Early Phase 1
Type 1 Diabetes
193 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4
Cardiovascular Disease
27 Actively Recruiting
Not Applicable, Early Phase 1, Phase 3, Phase 2
Type 2 Diabetes
167 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
Kidney Failure
40 Actively Recruiting
Phase 4, Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1
Physical Activity
24 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Insulin Resistance
0 Actively Recruiting
Renal Insufficiency
0 Actively Recruiting
Cardiovascular Mortality
0 Actively Recruiting
Ejection fraction decreased
0 Actively Recruiting
Hospitalizations
1 Actively Recruiting
Not Applicable
Diabetic Ketoacidosis
2 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Polycystic Ovarian Syndrome
6 Actively Recruiting
Not Applicable, Phase 1
inadequate response to metformin
0 Actively Recruiting
Heart Failure
0 Actively Recruiting
Diet
5 Actively Recruiting
Not Applicable, Phase 1
Diabetes Mellitus
0 Actively Recruiting

Riomet Reviews: What are patients saying about Riomet?

4.3Patient Review
10/8/2008
Riomet for Type 2 Diabetes Mellitus
This medication has been great for me. It's helped a lot with my diabetes pills, which I had a hard time swallowing before. My body got used to it quickly and I haven't experienced any negative side effects.
4.3Patient Review
5/17/2009
Riomet for Type 2 Diabetes Mellitus
I have trouble swallowing pills, so my doctor recommended this treatment to me as an alternative to Metformin. So far, it's been great! I haven't had any issues when taking it with a meal or snack.
3.7Patient Review
10/22/2010
Riomet for Type 2 Diabetes Mellitus
I was reading about potential side effects today and realized that some of the things I've been experiencing may be due to the medication. Also, as of today, the manufacturer is not producing the liquid form of Metformin due to "production problems." I can't swallow the big pills and need the liquid form, but now it might not be available until June!
2.7Patient Review
3/9/2016
Riomet for Type 2 Diabetes Mellitus
The flavor is incredibly off-putting. I'd recommend speaking to your pharmacist about adding a mango flavoring - it really helped me get the medicine down without gagging.
1.3Patient Review
7/3/2008
Riomet for Type 2 Diabetes Mellitus
Unfortunately, this medication caused me a lot of digestive problems.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about riomet

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Riomet used for?

"The drug is used to help control blood sugar levels in patients with type 2 diabetes. Managing blood sugar can help prevent serious diabetes-related problems, such as kidney damage, blindness, nerve damage, limb loss, and sexual dysfunction. Keeping diabetes under control may also reduce your risk of heart attack and stroke."

Answered by AI

Is Riomet available in the US?

"Riomet ER was approved by the U.S. Food and Drug Administration (FDA) to be taken once daily. It is the first and only FDA-approved liquid formulation of extended-release metformin."

Answered by AI

Is Riomet the same as metformin?

"Riomet is a prescription medication used to treat the symptoms of Type 2 diabetes. It may be used alone or with other medications. Riomet belongs to a class of drugs called Antidiabetics, Biguanides."

Answered by AI

What type of medication is Riomet?

"Riomet is a medication used to control blood sugar in patients with type 2 diabetes. It is to be used with a proper diet and exercise program, and possibly with other medications."

Answered by AI

Clinical Trials for Riomet

Image of Stanford University in Palo Alto, United States.

Decision Support Tool for Type 1 Diabetes

18 - 60
All Sexes
Palo Alto, CA
This study evaluates a digital decision-support tool designed to help individuals with type 1 diabetes prepare for exercise. This netIOB \& Exercise Tool (NEXT) uses glucose data and insulin delivery history to recommend individualized strategies such as carbohydrate intake, insulin adjustments, or delays in exercise start time. Participants will complete three structured aerobic or mixed-exercise sessions using different guidance approaches: (A) published consensus-based standard-of-care guidelines (B) usual personal care routines (C) the NEXT tool The study compares glucose outcomes, safety, and carbohydrate use across these conditions to inform better exercise preparation and support tools for people with diabetes.
Waitlist Available
Has No Placebo
Stanford UniversityRayhan Lal, MD
Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA
The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.
Recruiting
Has No Placebo
University of California, Los AngelesLauren E Wisk, PhD
Image of New York University Langone Health in New York, United States.

GGTA1 KO Thymokidney for Kidney Failure

40 - 70
All Sexes
New York, NY
The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow-up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, GGTA1 KO Thymokidney survival, and screening for zoonotic infections. Part B will continue for the lifetime of the participant or for 52 weeks following nephrectomy, if required.
Phase 1 & 2
Recruiting
New York University Langone HealthUnited Therapeutics
Have you considered Riomet clinical trials? We made a collection of clinical trials featuring Riomet, we think they might fit your search criteria.Go to Trials
Image of Medpace Clinical Pharmaology Unit in Cincinnati, United States.

PATAS for Type 2 Diabetes

18 - 55
All Sexes
Cincinnati, OH
The primary objective of Part 1 of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of Part 1 of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects. The primary objectives of Part 2 of this study are to evaluate the safety and tolerability of 4 weekly SC doses of PATAS in subjects with T2D; and to determine the PK and pharmacodynamics (PD) of 4 weekly SC doses of PATAS in subjects with T2D. The secondary objectives of Part 2 of this study are to evaluate the potential effect of multiple SC doses of PATAS on markers of glycemic control, as measured by glucose levels, insulin levels, and other metabolomic biomarkers; and to characterize the adverse event (AE) profiles of the various dose levels of PATAS.
Phase 1
Waitlist Available
Medpace Clinical Pharmaology UnitVincent Marion, Ph.D.AdipoPharma LLC
Have you considered Riomet clinical trials? We made a collection of clinical trials featuring Riomet, we think they might fit your search criteria.Go to Trials
Image of The Worship Center Cristian Church in Birmingham, United States.

Black Impact for Heart Health

18+
Male
Birmingham, AL
The goal of this clinical trial is to evaluate the implementation and effectiveness of the Black Impact program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * Does participation in the Black Impact program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)? * What factors influence the adoption, delivery, and sustainability of the Black Impact program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors. Participants will: * Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches. * Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care. * Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes. * Use a smartwatch, blood pressure cuff, and other tools to track progress in real time. * Participate in exit focus groups or interviews to share feedback about the intervention. * A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability. This study uses the RE-AIM framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.
Waitlist Available
Has No Placebo
The Worship Center Cristian Church
Have you considered Riomet clinical trials? We made a collection of clinical trials featuring Riomet, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security